{
    "organizations": [],
    "uuid": "53dc56221cac9b5e75c287e9ff224a723071b756",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-santhera-launches-us-expanded-acce/brief-santhera-launches-u-s-expanded-access-program-with-idebenone-for-patients-with-dmd-idUSFWN1PV1G2",
    "ord_in_thread": 0,
    "title": "BRIEF-Santhera Launches U.S. Expanded Access Program With Idebenone For Patients With DMD",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :\n* SANTHERA LAUNCHES U.S. EXPANDED ACCESS PROGRAM WITH IDEBENONE FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-06T14:24:00.000+02:00",
    "crawled": "2018-02-07T22:25:23.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "santhera",
        "pharmaceutical",
        "holding",
        "ag",
        "santhera",
        "launch",
        "expanded",
        "access",
        "program",
        "idebenone",
        "patient",
        "duchenne",
        "muscular",
        "dystrophy",
        "dmd",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}